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Abstract
Background:  Paratonia, a form of hypertonia, is associated with loss of mobility and with the
development of contractures especially in the late stages of the dementia.
Passive movement therapy (PMT) currently is the main physiotherapeutic intervention. General doubt
about the beneficial effects of this widely used therapy necessitates a randomised clinical trial (RCT) to
study the efficacy of PMT on the severity of paratonia and on the improvement of daily care.
Methods/Design: A RCT with a 4-week follow-up period. Patients with dementia (according to the
DSM-IV-TR Criteria) and moderate to severe paratonia are included in the study after proxy consent. By
means of computerised and concealed block randomisation (block-size of 4) patients are included in one
of two groups. The first group receives PMT, the second group receives usual care without PMT. PMT is
given according to a protocol by physical therapist three times a week for four weeks in a row. The
severity of paratonia (Modified Ashworth scale), the severity of the dementia (Global Deterioration Scale),
the clinical improvement (Clinical Global Impressions), the difficulty in daily care (Patient Specific
Complaints) and the experienced pain in daily care of the participant (PACSLAC-D) is assessed by
assessors blind to treatment allocation at baseline, after 6 and 12 treatments.
Success of the intervention is defined as a significant increase of decline on the modified Ashworth scale.
The 'proportion of change' in two and four weeks time on this scale will be analysed. Also a multiple logistic
regression analysis using declined/not declined criteria as dependent variable with correction for relevant
confounders (e.g. stage of dementia, medication, co-morbidity) will be used.
Discussion: This study is the first RCT of this size to gain further insight on the effect of passive
movement therapy on the severity of paratonia.
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Background
Paratonia is one of the motor problems seen in persons
with dementia and was first described by Dupré in 1910
as the inability to relax muscles in combination with a
mental disorder [1]. Paratonia is hypothesized to develop
centrally but to exert an effect on peripheral biomechan-
ics. Especially in the late stages of dementia it is associated
with loss of mobility and with the development of con-
tractures [2-5]. Thus, paratonie has a negative impact on
the quality of life and can result in problems with washing
and dressing
The prevalence of paratonia ranges from 5% in the early
stages of dementia to 100% in the advanced stages [2,5].
We found an estimated prevalence of paratonia of approx-
imately 80% in a group of Dutch nursing home patients
with dementia [6]. Passive movement therapy (PMT) is a
therapeutic intervention designed to increase the passive
extensibility of muscles, ligaments and collagen in order
to achieve maximal joint range of motion [7,8]. A recent
NIVEL report revealed that PMT is with 28.2% one of the
main physiotherapeutic interventions in Dutch nursing
homes, with an average duration of 30 minutes per
patient per week [9]. This therapy is generally believed to
be effective in patients with paratonia [10,11]. Profes-
sional workers claim that this therapy, if given shortly
before washing and bathing, facilitates the care for the
patients, due to improved range of motion of affected
limbs. Investigations in other populations, e.g., patients
with spasticity and contractures show a temporal effect or
a so-called elastic deformation due to the visco-elastic
properties in all tissues [7]. However, after 20 to 30 min-
utes, joint range of motion returns to the starting values.
Plastic deformation, or a permanent effect, is only possi-
ble if the patient can actively use the gained mobility[7,8].
Furthermore, animal studies indicate that when activated
muscles fibres are stretched, which is the case with PMT in
paratonia, older tissues are more susceptible to injury on
sarcomere level [12]. Given the fact that these frail
patients, who often show signs of discomfort during the
treatment, are prone to injury and are not able to actively
use regained mobility PMT is controversial. Nonetheless,
maybe because of a lack of alternatives, or because of pres-
sure of concerned relatives, physicians and physiothera-
pist start PMT. A pilot study in 15 patients with paratonia
confirmed that PMT had positive short term effects, but
trend analyses of long term effects showed that after 3
weeks hypertonia increased slightly in 30% in the PMT
group in comparison with 10% in the control groups,
indicating a possible association with muscle fibre inju-
ries [3]. We feel this is a relevant finding, however, the
small sample size of this pilot study, and the lack of a clear
operational definition of paratonia did not allow for firm
conclusions concerning the efficacy of PMT.
Before designing a new trial with sufficient power we
therefore initiated a Delphi procedure with known experts
in the field to achieve a new consensus definition of para-
tonia. After four Delphi-rounds, the experts agreed on 7
criteria for operational defining paratonia (see below)
[13]. Consequently these criteria have been assessed on
validity and reliability in a 3-phase cross-sectional study
in which this definition was tailored even further and in
which we developed an assessment instrument (the Para-
tonia Assessment Instrument, PAI) for an instant diagno-
sis of paratonia, thus providing researchers an operational
tool for future trials on paratonia [6].
"Paratonia is a form of hypertonia with an involuntary variable
resistance during passive movement. The nature of paratonia
may change with progression of the dementing illness (e.g.
active assistance (Mitgehen) is more common early in the
course of degenerative dementias, whilst active resistance is
more common later in the course of the disease). The degree of
resistance varies depending on the speed of movement (e.g. a
low resistance to slow movement and a high resistance to fast
movement). Paratonia increases with progression of dementia.
Furthermore, the resistance to passive movement is in any
direction and there is no clasp-knife phenomenon." The resist-
ance must be felt in either two directions in one limb or in two
different limbs.
We designed a randomized clinical trial in order to answer
three research questions; first, is passive movement ther-
apy an effective intervention on the severity of paratonia
in comparison with usual care without passive movement
therapy?
Second, is passive movement therapy an effective inter-
vention for improvement of daily care? And finally, does
PMT reduce pain during daily care in patients with mod-
erate to severe paratonia.
Methods
To answer these 3 research questions we use a randomised
clinical trial with 4 weeks of follow-up.
Patients
The study population consists of patients with dementia
(according to the DSM-IV-TR Criteria) and established
paratonia according to the Paratonia Assessment Instru-
ment (PAI). The PAI is a construct of five criteria derived
from the definition, representing distinct elements of the
clinical manifestation of paratonia [6]. The resistance felt
during passive movement due to paratonia has to be at
least in one of the limbs more marked i.e. a score of 2 or
more on the modified Ashworth scale. Possible partici-
pants will be identified by trained personnel of participat-
ing nursing homes. After identification of participants the
researcher checks if the patient is eligible for the study andBMC Geriatrics 2007, 7:30 http://www.biomedcentral.com/1471-2318/7/30
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if so will contact the legal representative(s) of the patient
by sending an information leaflet about the study.
Patients are only included after proxy consent. Because
patients are included after proxy consent we will exclude
participants who indicate during the trial in any way, ver-
bally or nonverbally, not to approve of participation.
Patients with an unstable disease, as judged by the nursing
home physician, such as progressive malignant cancer or
other diseases with an obvious progressive negative effect
on the motor function or health status are excluded as
well as patients who received passive movement therapy
within a period of 4 weeks prior to admission or who
receive typical or a-typical antipsychotics.
Interventions
Patients are included in one of two groups after computer-
ised and concealed block randomisation (block size of
four). The first group receives usual care with PMT, the
second group receives usual care without PMT. Usual care
generally consists of grooming and dressing with slow and
gentle movements by trained nurses. Some of the partici-
pants wear especially designed clothing that enables the
nurses to dress patients more easy while the patient is
lying in bed or sitting in a wheelchair. Most participants
use cushions, mostly manufactured on demand, for a sta-
ble position in bed and sit during the day time in comfort-
able wheelchairs.
PMT is provided in a standardized way. During the first
part of passive movement the therapist moves slowly the
affected limbs, with the emphasis on lowering the resist-
ance. After this, the therapist tries to reach the end range
of motion and possibly stretches the structures very lightly
without causing pain. The patients are positioned com-
fortably supine in bed while the therapist starts PMT with
the left arm moving it in flexion and extension (up and
down). Subsequently PMT is performed on the right arm,
left leg and finally the right leg. The duration of PMT is
approximately 20 minutes per patient per session. The
treatment group receives PMT, between 8 a.m. and 10
a.m., shortly before being washed and dressed by nursing
staff, three times a week for four weeks in a row. In order
to safeguard blinding of the assessors for treatment alloca-
tion, the control group receives a placebo treatment in the
same frequency and in the same time frame. The patients
of the control group are positioned comfortably supine in
bed after which the therapist stays in the room for approx-
imately 20 minutes. On every treatment day a special sign-
board on the participant's bedroom door indicates that
research is going on advising nursing staff to delay their
activities with the participant and not disturb the treat-
ment session.
Outcome measures
The Modified Ashworth scale is the primary outcome
measure and tested with an acceptable reliability to assess
the severity of paratonia (intrarater reliability; Kendall's
Tb 0.62–0.80 and interrater reliability; Kendall's Tb 0.72–
0.77) [14]. It is a 5 point scale ranging from 0 to 4, in
which 0 = no resistance to passive movement, 1 = slight
resistance during passive movement, 2 = more marked
resistance to passive movement, 3 = considerable resist-
ance to passive movement, 4 = severe resistance, passive
movement is impossible. Severity of paratonia will be
assessed by assessors blinded to treatment allocation at
baseline one day prior to treatment start, one day after
treatment 6 (after 2 weeks) and one day after treatment 12
(after 4 weeks) between 8 a.m. and 10 a.m. before wash-
ing and dressing by nursing staff.
To assess the severity of paratonia all four limbs will be
passively moved in flexion and extension with the partic-
ipant in a comfortable position supine in bed.
As secondary outcome measures we assess The Pain
Assessment Checklist for Seniors with Limited Ability to
Communicate (PACSLAC-D) [15,16], to assess a decrease
of pain as a possible side effect of PMT The PACSLAC-D is
an observational assessment instrument that lists 24 items
divided in three categories; nonverbal facial signs (10
items), total resistance (6 items) and emotional state (8
items). This version, a reduction of the original 60 item
PACSLAC scale had high levels of internal consistency for
the complete scale (Cronbach's alpha range 0.82–0.86)
and for all subscales (alpha range 0.72–0.82) [17].
An independent observer will assess the PACSLAC-D in
both groups by a 5-minute observation of washing and
dressing within an hour after the first, sixth and the
twelfth treatment session. Another secondary outcome
measure is the Clinical Global Impressions scale (CGI) to
assess clinical change. With this CGI, especially appointed
nurses, who are blinded for treatment allocation, compare
the participant with all other patients with paratonia on
their ward on a 7 point scale from normal to most severe
and rate after 2 and 4 weeks the global improvement also
on a 7 point scale from very much improved to very much
worse. Finally, the modified "Patient Specific Complaint"
(PSC) assessment is used, in which the nurses are asked to
address the 3 most difficult items in daily care and rate
these items on a visual analogue scale of 100 mm, with at
the extreme ends "no trouble at all" and "impossible". The
frequencies of all assessments are illustrated in Table 1.
At baseline we will register demographic information and
relevant variables such as age, sex, use of medication, type
of dementia and severity of the dementia. Severity of
dementia is assessed with the Global Deterioration ScaleBMC Geriatrics 2007, 7:30 http://www.biomedcentral.com/1471-2318/7/30
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which consists of seven stages of cognitive decline in
which stage 1 = no cognitive decline, level 2 = very mild
cognitive decline, level 3 = mild cognitive decline, level 4
= moderate cognitive decline, level 5 = moderately severe,
level 6 = severe and level 7 = very severe cognitive decline
[18]. Psychoactive medications will be classified using the
Anatomical Therapeutical Chemical-classification and
grouped into antipsychotics, anxiolytics, hypnotics/seda-
tives, antidepressants, anti-epileptics and miscellaneous
(e.g. cholinesterase inhibitors) [19].
Sample size
The Modified Ashworth Scale is our primary outcome
measure. A trend analysis of the pilot study data showed a
worsening of paratonia in 30% of the group with PMT
and in 10%, possibly due to natural course, of the group
with usual care without PMT [3]. We consider this effect as
clinical important. With an alpha of 0.05 and a power of
80% a sample size of 69 patients per group (taking into
account a drop-out percentage of 10%) is needed to detect
this effect.
Analysis
All data will be analysed with SPSS 15.0. The Modified
Ashworth scale, an ordinal 5-point scale, will be measured
at 3 times, at baseline (T0) after 2 weeks (T1) and after 4
weeks (T2). Our premise in this study is that PMT causes
an accelerated worsening of paratonia over 4 weeks time.
Success of the intervention is defined as a significant (p <
0.05) difference between the proportion of change on the
modified Ashworth scale in the two groups.
To determine any development or change over time of
The Modified Ashworth score in the two groups the Stu-
art-Maxwell statistic will be used.
The difference in proportion of change between the two
groups will be calculated and tested for significance [20].
However controlling for relevant confounders e.g. age,
sex, severity and type of dementia is not possible with this
analysis. Therefore a multiple logistic regression analysis
will be performed on the dichotomised outcome meas-
ure, "declined" and "stable/improved", of the difference
on T0 and T2 on The Modified Ashworth score.
Missing data will be assumed to be missing at random.
The Last Observation Carried Forward method will be
used in those cases with no last measurement (T2) yet
with valid data from the second assessment (T1). Analyses
will be carried out according to the intention to treat prin-
ciple.
Study timeline
The estimated project time is 18 months. The project will
start with an extensive training of relevant staff of all par-
ticipating nursing homes. The training period will take
two months. After this training the inclusion period will
start and will run for twelve months. Analysis of data and
writing of the report is estimated to take 4 months.
The study has been approved by the local ethical commit-
tee CMO nr. 2006/1567, ABR file nr. NL13777.091.06.
The investigator will notify the accredited local ethical
committee of the end of the study within a period of 8
weeks. The end of the study is defined as the last patient's
last follow-up measurement. Within one year after the
end of the study the investigator will submit a final study
report with the results, including any publication/
abstracts of the study to the accredited local ethical com-
mittee. The investigators are not restricted in any way to
publish the results of the study.
Discussion
This study is the first RCT of this size to gain further
insight on the effect of passive movement therapy on the
severity of paratonia.
Ethical aspects
PMT is a very common physiotherapeutic intervention in
patients with moderate to severe paratonia. Although it is
controversial and possibly harmful for these frail elderly,
in lack of evidence based alternative interventions, most
therapists perform PMT. For this reason we designed this
Table 1: Assessment schedule
Assessment scale (Assessed by) T0 T1 T2
Modified Ashworth (Assessor, 
blind for treatment allocation)
One day prior to treatment start One day after treatment 6 One day after treatment 12
PACSLAC (independent asses-
sor, blind for treatment alloca-
tion)
on the day of the first treatment On the day of the sixth treatment On the day of the twelfth treatment
CGI and PSC (Nurse, blind for 
treatment allocation)
One day prior to treatment start One day after treatment 6 One day after treatment 12
GDS (Nurse) Within a week before trial startBMC Geriatrics 2007, 7:30 http://www.biomedcentral.com/1471-2318/7/30
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RCT in a very pragmatic way, close to daily practice
bounded by ethical aspects limiting the time frame of 4
weeks per participant and using assessment tools that are
valid and reliable but above all with a minimal burden for
the frail participants. Although we realise that further
assessments after the end of the treatment period could
have given more insight in the duration of the effect of
PMT, the frailty of the participants prevails over the aims
of research. For the same reason we decided to use no
invasive methods, such as muscle biopsy to assess possi-
ble tissue damage.
Bias
With the use of the consensus definition a homogeneous
population should be guaranteed although research in the
more severe cases of paratonia indicates that if the resist-
ance in affected limbs is very high the assessor is not able
to accelerate the movement and adequate differentiation
with Parkinsonian (lead pipe) rigidity becomes impossi-
ble [6]. Furthermore, we did not specify the type of
dementia in the inclusion criteria. At this moment we
know that in the advanced stages of the disease all patients
have paratonia. However, it is unclear if there are any dis-
similarities in the development and severity of paratonia
in different types of dementia. Therefore paratonia, diag-
nosed in different dementias, could react inconsistently to
PMT and although we take this into account in our analy-
sis this uncertainty could be a potential source of bias.
With this study, we hope to clarify the effect of passive
movement therapy on moderate to severe paratonia and
hopefully gain some scientific basis for the use of this
treatment or to abandon PMT in this population. The con-
troversy between the hypothesis of the research team that
PMT is possibly harmful and the assumption of nurses
and relatives that it is beneficial, necessitates a thorough
organisation for keeping all assessors blind for treatment
allocation. Therefore randomisation is done in a block
size randomisation system with block size of four. For
each participating nursing home a new sequence is calcu-
lated at the faculty of Epidemiology of the Maastricht Uni-
versity. The blinding of the assessors can be compromised
by an incidental verbal hint of one of the participants
although most of the participants are in the advanced
stage of dementia and lost there capacity of speech.
validity
The research will be conducted in four different nursing
homes, that will enhance extrapolation of study findings.
However, due to the fact that at least 4 different geriatric
physical therapists will perform PMT and at least two dif-
ferent assessors of the severity of paratonia will partici-
pate, the internal validity may become compromised. A
protocollized way of performing PMT and an extensive
training of all therapists and assessors involved should
ensure internal validity of this study and reliability of
assessed outcomes.
The results of this randomised controlled trial will be pub-
lished in a scientific journal and will be used for recom-
mendations in the guideline of geriatric physical therapy
and implemented in current physical therapy practice.
This guideline will be developed according to method of
clinical practice guideline development of the Royal
Dutch Physiotherapy Association (KNGF) [21].
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